Interleukin-11.

Interleukin-11. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Interleukin-11. Abstract Text:

A J Dorner,S J Goldman,J C Keith,

Interleukin-11 (IL-11) is a cytokine which interacts with a variety of haemopoietic and non-haemopoietic cell types. Recombinant human IL-11 (rhIL-11; oprelvekin) is produced in Escherichia coli and differs from the naturally occurring protein only in the absence of the amino-terminal proline residue. In synergy with other factors, rhIL-11 stimulates the growth of myeloid, erythroid, and megakaryocyte progenitor cells in vitro. In vivo, rhIL-11 is active in mice, rats, dogs, guinea pigs, hamsters and non-human primates, where the principal activity measured was stimulation of megakaryocytopoiesis and thrombopoiesis. rhIL-11 has shown benefit in 2 clinical trials by significantly reducing severe chemotherapy-induced thrombocytopenia. In addition to its thrombopoietic activity, rhIL-11 has also shown activity in models of acute gastrointestinal mucosal damage. rhIL-11 enhanced survival in mice following cytoablative therapy and in a hamster model of chemotherapy-induced oral mucositis, where treatment with rhIL-11 was associated with decreased mucosal damage, accelerated healing and reduced numbers of deaths. rhIL-11 is currently in clinical trials for the treatment of chemotherapy-induced mucositis. In rat models of acute colonic injury and inflammatory bowel disease, rhIL-11 treatment reduced intestinal mucosal damage and alleviated clinical signs. rhIL-11 has direct effects on activated macrophages to reduce the production of pro-inflammatory mediators. In animal models of endotoxaemia, rhIL-11 treatment reduced serum levels of pro-inflammatory cytokines and blocked hypotension. rhIL-11 increased survival in models of Gram-negative sepsis and toxic shock. Based on these studies, rhIL-11 is currently in clinical trials for treatment of Crohn's disease. Other inflammatory conditions are being further evaluated. Mechanistically, rhIL-11 functions at many levels to control inflammation, ameliorate tissue damage and maintain haemostasis in the face of trauma or infection. rhIL-11 has direct effects on hepatocytes, inducing the production of acute phase reactant proteins, haem oxygenase and tissue inhibitor of metalloproteinase-1 (TIMP-1). TIMP-1 expression can also be induced in synoviocytes and chondrocytes by treatment with rhIL-11. rhIL-11 administration has been associated with increased plasma levels of von Willebrand factor and fibrinogen. rhIL-11 treatment potentially offers multiple benefits for cancer chemotherapy patients, such as prevention of thrombocytopenia, gastrointestinal epithelial protection and subsequent reduction of mucositis, and amelioration of inflammatory complications. In addition, rhIL-11 is being evaluated further in the treatment of inflammatory disorders such as inflammatory bowel disease, rheumatoid arthritis and sepsis.

Interleukin-11. Publishing Authors By Initials

AJ Dorner,SJ Goldman,JC Keith,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Interleukin-11. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: BioDrugs : clinical immunotherapeutics, biopharmac

VOLUME: 8

Page Numbers: 418-29

Journal Abbreviation:

ISSN: 1173-8804

DAY: 22

MONTH: Dec

YEAR: 1997

Interleukin-11. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9705305

Interleukin-11. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Interleukin-11. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Interleukin-11.

AFFILIATION: Department of Preclinical Research and Development, Genetics Institute Inc., Cambridge, Massachusetts, USA.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: BioDrugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Interleukin-11 Related Publications

• A comparison of general and age-specific factors associated with political behavior.
• Angiocardiography in infants and children.
• Complications of temporomandibular joint surgery.
• Decreased waiting periods in a public pregnancy termination clinic.
• Electrode fracture rates and occurrences of infection and granuloma associated with percutaneous intramuscular electrodes in upper-limb functional electrical stimulation applications.
• Epigenetic control of cellular senescence in disease: opportunities for therapeutic intervention.
• Feedback to doctors about prescribing errors in the hospital setting.
• Headache, irritability and fatigue.
• INTRAVENOUS UREA IN GLAUCOMA.
• Interleukin-11.
• Introduction and Overview: 481: 9:00 AM-9:10 AM.
• Joint ventures and home health care.
• Linking leaf and tree water use with an individual-tree model.
• Mercury transport and bioaccumulation in riverbank communities of the Alvarado Lagoon System, Veracruz State, Mexico.
• Nursing home administrators' views of their own and volunteer resident advocates' enhancement of long-term care.
• One step conversion of heteroaromatic-N-oxides to imidazolo-heteroarenes.
• Physicians' opinions of expanded clinical pharmacy services.
• Preliminary open trial of interpersonal counseling for subsyndromal depression following miscarriage.
• Prolonged penicillemia following the intramuscular injection of benzethacil in children.
• Putting laparoscopy on the academic map: early and continuing scholarship by the AAGL.
• Sir Arthur Keith centenary.
• Some observations on diminished responsibility.
• Stem cell ageing: does it happen and can we intervene?
• Subdural empyema.
• Targeting telomerase for cancer therapeutics.
• Telomerase redefined: Integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity.
• The influence of pteroylglutamic acid on glycine and on porphyrin metabolism.
• The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action.
• The work-satisfaction, retirement-attitude typology: profile examination.
• [Sterilization using the laparoscope]